X4 Pharmaceuticals to Announce Second Quarter 2020 Financial Results and Host a Conference Call and Webcast on July 30, 2020

Rhea-AI Summary

X4 Pharmaceuticals (Nasdaq: XFOR) announced plans to report its financial results for Q2 2020 on July 30, 2020. The earnings call will provide insights into recent business highlights and will take place at 8:30 a.m. ET. The company focuses on treating diseases linked to CXCR4 pathway dysfunction, with its lead candidate, mavorixafor, undergoing multiple clinical trials, including a Phase 3 trial for WHIM syndrome. Interested parties can access the live webcast via the company's investor relations webpage.

Positive

• Mavorixafor undergoing a global Phase 3 clinical trial for WHIM syndrome.
• Lead candidate mavorixafor being evaluated in two Phase 1b clinical trials.

Negative

• None.

CAMBRIDGE, Mass., July 16, 2020 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today announced that it will report its financial results for the second quarter ended June 30, 2020, and provide an update on recent business highlights, on July 30, 2020.

The Company will host a conference call and webcast on the same day at 8:30 a.m. ET to discuss these financial results and business highlights. The conference call can be accessed by dialing (866) 721-7655 from the United States or (409) 216-0009 internationally, followed by the conference ID: 6091009. The live webcast can be accessed on the investor relations section of X4 Pharmaceuticals’ website at www.x4pharma.com. Following the completion of the call, a webcast replay of the conference call will be available on the website.

About X4 Pharmaceuticals
X4 Pharmaceuticals is a late-stage clinical biopharmaceutical company and a leader in the discovery and development of novel therapies for the treatment of diseases resulting from dysfunction of the CXCR4 pathway, with a focus on rare diseases and those with limited treatment options. The Company’s lead candidate, mavorixafor, is a first-in-class, small molecule antagonist of chemokine receptor CXCR4 being developed as a once-daily oral therapy. X4 believes that inhibition of the CXCR4 receptor creates the potential for mavorixafor to provide therapeutic benefit across a wide variety of diseases, including primary immunodeficiencies and certain types of cancer. The efficacy and safety of mavorixafor, dosed once daily, is currently being evaluated in a global Phase 3 clinical trial in patients with WHIM syndrome, and in two Phase 1b clinical trials – as monotherapy in patients with Severe Congenital Neutropenia (SCN) and in combination with ibrutinib in patients with Waldenström’s macroglobulinemia. X4 is continuing to leverage its insights into CXCR4 biology at its corporate headquarters in Cambridge, Massachusetts and at its research facility in Vienna, Austria, and is discovering and developing additional product candidates. For more information, please visit www.x4pharma.com.

Investors and Media: 
Candice Ellis, 857-341-1043 
Director, Corporate Communications & Investor Relations 
Candice.Ellis@x4pharma.com

FAQ

When will X4 Pharmaceuticals report its Q2 2020 financial results?

X4 Pharmaceuticals will report its Q2 2020 financial results on July 30, 2020.

What time is the X4 Pharmaceuticals conference call for Q2 2020 results?

The conference call for Q2 2020 results will be held at 8:30 a.m. ET on July 30, 2020.

What is mavorixafor, the lead candidate of X4 Pharmaceuticals?

Mavorixafor is a first-in-class, small molecule antagonist of chemokine receptor CXCR4.

What clinical trials is X4 Pharmaceuticals conducting?

X4 Pharmaceuticals is conducting a global Phase 3 trial for WHIM syndrome and two Phase 1b trials for other conditions.

How can I access the X4 Pharmaceuticals earnings call?

The earnings call can be accessed by dialing (866) 721-7655 in the U.S. or (409) 216-0009 internationally, with conference ID: 6091009.